Company Overview and News

0
Maharashtra Scooters Limited - AGM/Book Closure

2018-05-16 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
MAHSCOOTER 500266

0
Maharashtra Scooters Limited - Dividend

2018-05-16 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
MAHSCOOTER 500266

0
Maharashtra Scooters Limited - Change in Director(s)

2018-05-16 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
MAHSCOOTER 500266

0
Maharashtra Scooters Limited - Financial Result Updates

2018-05-16 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
MAHSCOOTER 500266

0
Maharashtra Scooters Limited - Change in Director(s)

2018-05-10 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
MAHSCOOTER 500266

24
Market Live: Nifty holds 10,550; FMCG index up 2%, Bharti Group stocks gain

2018-04-18 moneycontrol
12:55 pm Earnings Outlook: "We are looking at Sensex earnings. In Q4, earnings will grow in the range of 13-14 percent, which will be double digit growth after a long time. Partially, this will be due to low base of Q4 last year and the other due to better earnings of global commodity companies, be it energy or metals. That will aid overall growth,” Gaurav Dua, Head of Research, Sharekhan told Moneycontrol.
BAJAJ-AUTO ESL AMKD DABUR FEDA ICLQY SIMMOND DBRQY 500096 MAHSCOOTER 534816 UCLQY FEDS 500850 GODREJCP FEDERALBNK EICHERMOT GLENMARK JAGRAN 532705 FDBAY YYBKY 532822 MRZUY ULTRACEMCO 532424 532500 BAJAJFINSV TATASTEEL FORTIS TATLY MARUTI 500266 504741 BHRYY 500469 AMTEKAUTO 532978 532538 532977 BHRQY GLKQY GDRJY 505200 500470 INFRATEL BHARTIARTL INDHOTEL YESBANK ECQRY 500314 ORIENTHOT 533264 UCLQF 532648 532843 532454 TTST INDIANHUME 532296 IDEA 520077 507998

20
Market Live: Sensex consolidates after 9-day gains; hotels stocks extend rally

2018-04-18 moneycontrol
10:55 am Should gold be a part of your portfolio?: Akash Jain, Vice President - Equity Research, Ajcon Global said gold is better as a short to medium-term investment, as long-term returns on the yellow metal are often as low as 10 percent per annum. We would suggest investors not to make too heavy or long-term investments in gold.
BAJAJ-AUTO ESL DABUR 532538 532978 532977 SIMMOND BHRQY DBRQY GLKQY 505200 500096 500470 MAHSCOOTER UCLQY 500850 BHARTIARTL INDHOTEL EICHERMOT GLENMARK YESBANK ECQRY JAGRAN 500314 ORIENTHOT 532705 533264 UCLQF 532648 YYBKY 532843 ULTRACEMCO 532454 BAJAJFINSV TTST 532296 INDIANHUME TATASTEEL FORTIS TATLY 500266 504741 507998

17
Market Live: Sensex off opening high, midcaps outperform; Mindtree hits new high

2018-04-18 moneycontrol
9:55 am Buzzing: Simmonds Marshall share price rallied 10 percent after ICICI Research said the company has a capital efficient business model where it realises around 3x asset turnover, realises around 12-13 percent EBITDA margins and has a working capital cycle of around 130 days.
DABUR 532538 532978 SIMMOND BHRQY DBRQY GLKQY 505200 500096 500470 MAHSCOOTER UCLQY BHARTIARTL EICHERMOT GLENMARK YESBANK ECQRY JAGRAN 532705 UCLQF 532648 YYBKY 532843 ULTRACEMCO 532454 BAJAJFINSV TTST 532296 INDIANHUME TATASTEEL FORTIS TATLY 500266 504741 507998

0
Maharashtra Scooters Limited - Disc. under Reg.30 of SEBI (SAST) Reg.2011

2018-04-09 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
MAHSCOOTER 500266

0
Maharashtra Scooters Limited - Change in Director(s)

2018-04-06 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
MAHSCOOTER 500266

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...